Assenfali n ukansir n tgezzayt yeṭṭef deg waṭas n yimgan, gar-asen aswir n ukansir, leɛmer d tezmert n umdan s umata, d tneflit n usafar.
S umata, akken yettwaf kan s zzerb aken yettwaṭṭef ukansir, akken i yelha ussumer.
Ɣef leḥsab n Tiddukla Tamarikant n Kunsir, aswir n temudert n 5 n yiseggasen i kunsir n tgezzayt d wazal n 65% i yal aswir akken ma yella.
D acu kan, i ukunsir n teɣmest (asurif 1), azref n temudert n 5 n yiseggasen d azal n 90%, ma d win n ukunsir n teɣmest (asurif 4) yebɛed, azref n temudert n 5 n yiseggasen d azal n 111%.
Li YD, Lv Z, Xie HY, Zheng SS: Retinoblastoma binding protein 4 up-regulation is correlated with hepatic metastasis and poor prognosis in colon cancer patients. Hepatobiliary Pancreat Dis Int. 2019, 18 (5): 446-451.
Di W, Li X, Yang Q: Polysaccharide of Lactobacillus casei SB27 reduced colon cancer cell prognosis through mitochondrial damage by upregulation of HINT2. Asia Pac J Clin Oncol. 2022, (): .
Kong D, Li G, Yang Z, Cheng S, Zhang W, Feng L, Zhang K: Identification of an ACK1/TNK2-based prognostic signature for colon cancer to predict survival and inflammatory landscapes. BMC Cancer. 2022, 22 (1): 84.
Zeng C, Huang L, Zheng Y, Huang H, Chen L, Chi L: [Expression of transcriptional coactivator with PDZ-binding motif (TAZ) in colon cancer tissues and its clinical significance]. Zhonghua Wei Chang Wai Ke Za Zhi. 2015, 18 (11): 1154-7.
Tang S, Yuan X, Song J, Chen Y, Tan X, Li Q: Association analyses of the JAK/STAT signaling pathway with the progression and prognosis of colon cancer. Oncol Lett. 2019, 17 (1): 159-164.
Wang GQ, Lu ZH, Fang YJ, Chen G, Zhou ZW, Pan ZZ, Wan DS: [Expression and clinical significance of survivin and matrix metalloproteinase-7 in colon cancer]. Ai Zheng. 2009, 28 (9): 945-9.
['Anfafad: amejjay']
['Asmel-a web yettunefk-d kan i yiswiyen n uselmed d usissen, ur d-yettak ara iwellihen imejjayen neɣ isefka udmawanen.']
['Isallen i d-yettunefken ur ilaq ara ad ttwasqedcen i usebded neɣ i usemḥi n kra n wugur n tezmert neɣ aṭṭan, yerna wid yettnadin ɣef yiwellihen imsujjiyen udmawanen yessefk ad ẓren amejjay yesɛan turagt.']
['Ttxil-k ẓer belli azeṭṭa amseddayan i d-yettaken tiririyin i tuttriwin, ur iṣeḥḥa ara mliḥ ma yella d ayen yerzan uḍḍun. D amedya, amḍan n yimdanen yettwaḍḍfen s kra n waṭṭan.']
['Ssutur dima ṛṛay n ṭṭbib-ik neɣ n kra n umejjay-nniḍen ara iwalmen ɣef waṭṭan-ik. Ɣur-k ad tḥeqreḍ ṛṛay n ṭṭbib amsadur neɣ ad tεeṭṭleḍ deg usuter-is ɣef lǧal n kra i teɣriḍ deg usmel-a. Ma tɣileḍ ahat tesεiḍ liḥala n tεeǧlanit deg tezmert, siwel 911 neɣ ṛuḥ ɣer texxamt n tεeǧlanit i d-iqerben. Ulac assaɣ gar ṭṭbib d umuḍin i d-yettnulfun s usmel-a neɣ aseqdec-is. BioMedLib neɣ ixeddamen-is, neɣ kra n win yettekkiyen deg usmel-a, ur d-ttaken ara yakk kra n yisumren, s wawal neɣ s usemres, ɣef ayen yerzan isallen i d-yettunefken dagi neɣ aseqdec-is.']
['Anekcum: azref n uḍfar']
['Asaḍuf n umeskar n yizerfan n wemdan n alfin (Digital Millennium Copyright Act) n 1998, 17 U.S.C. § 512 (DMCA) yettak-d ttawil i yimeskaren n yizerfan n wemdan i yumnen belli ayen i d-yettbanen deg Internet yettḍurru izerfan-nsen ddaw usaḍuf n umeskar n yizerfan n wemdan n Marikan. ']
['Ma tumneḍ s wul yelhan belli kra n taɣult neɣ taɣawsa yettwafken deg unermes-nneɣ neɣ deg yiqeddacen-nneɣ tegzem azref-ik n uḥraz, tzemreḍ (neɣ amsedday-ik) ad aɣ-d-tazneḍ izen akken ad nessuter asuffeɣ n taɣult neɣ n taɣawsa-nni, neɣ ad nessader tuqqna ɣer-s. ']
['Isental yessefk ad ttwazen s tira s yimayl (ẓer asebter "Contact" i tansa n yimayl).']
['DMCA teḥwaǧ isalli-inek n tukksa n yizerfan yettwanekṛen ad d-yeglu s yisallen-a: (1) asegzi n umahil yettwaḥerzen s yizerfan yettwanekṛen i d-yettwanekren; (2) asegzi n uḍris yettwanekren d yisallen ara aɣ-yeǧǧen ad d-naf uḍris-nni; (3) isallen n usiwel inek, ladɣa tansa-inek, uṭṭun n tilifun d tansa imayl; (4) awal sɣur-k d akken tumneḍ s wayen yelhan belli aḍris-nni s wamek i d-tettcetkiḍ ur yettwasemres ara sɣur bab n yizerfan, neɣ amesten-is, neɣ s useqdec n kra n usaḍuf; ']
['(5) yiwet n tseddi sɣur-k, yettwatten s uḥasef n lekdeb, d akken isallen yellan deg uzenzi d iṣeḥḥan u tesεiḍ azref ad tesseḍruḍ izerfan umeskar i d-yeqqaren ttwarẓen; ']
['akked (6) azmul n tfekka neɣ n tuqqna tagensit n bab n yizerfan neɣ n umdan yettwafernen ad yexdem s yisem n bab n yizerfan. ']
['Ma ur d-terriḍ ara isallen-agi akk, yezmer ad d-yeglu s uεeṭṭel deg usefrek n ucetki-inek.']
['Assaɣ']
['Ttxil-k azen-aɣ-d imayl ma tesεiḍ asteqsi / asumer.']
What is prognosis of colon cancer?
The prognosis of colon cancer depends on several factors, including the stage of the cancer, the patient's age and overall health, and the effectiveness of treatment.
In general, the earlier the cancer is detected and treated, the better the prognosis.
According to the American Cancer Society, the 5-year relative survival rate for colon cancer is about 65% for all stages combined.
However, for localized colon cancer (stage 1), the 5-year relative survival rate is about 90%, while for distant (stage 4) colon cancer, the 5-year relative survival rate is about 111%. It is important to note that these are only estimates and that individual outcomes may vary.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Ɣef']
['BioMedLib yesseqdac iselkimen imseddayen (algoritmes n ulmad n tnaεurt) i usnulfu n tuqqniwin n tuttriwin d tririyin.']
['Nebda s 35 imelyan n teẓrigin n tesnujjya tameddurt n PubMed/Medline. Rnu daɣen, isebtar n web n RefinedWeb.']
